Device Trial Radar · NCT03200288
A Study to Evaluate the Clinical Performance and Safety of an Intra-articular Hyaluronic Acid in Knee Osteoarthritis
Last checked: Nov 19, 2026Latest source record: Nov 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
692
Actual
Start
Jun 29, 2017
Primary completion
Jun 27, 2018
Study completion Oct 30, 2018
Sponsor
- Lead sponsor
- IBSA Institut Biochimique SANot on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the Clinical Performance and Safety of a single intra-articular (i.a.) injection of hyaluronic acid product (as HL-01) in the treatment of pain due to osteoarthritis (OA) of the knee.
Conditions
- Knee Osteoarthritis
Interventions
HL-01: high and low molecular weight hyaluronic acidDevice
2 ml intra-articular single injection
PlaceboDevice
2 ml intra-articular single injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in VAS (Visual Analogue Scale) pain scoreTime frame: Baseline-week 24
Locations
31 sites in 5 countries. Site status is shown where the registry gives one.
CHU Centre Ville (Brull) - Bone Metabolism Unit
Liège, Belgium
Rheumazentrum Prof. Dr. med. Gunther Neeck
Bad Doberan, Germany
Klinische Forschung Berlin-Mitte GmbH
Berlin, Germany
28 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.